Clincosm LogoSign in Get a demo

Refractory Mantle Cell Lymphoma

Showing 1 - 25 of 29
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Rochester (procedure, drug, biological)

Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biopsy
  • +10 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 9, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Low Dose Radiation Therapy)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Low Dose Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Duarte, California
  • +1 more
Aug 3, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle

Not yet recruiting
  • Post-Transplant Lymphoproliferative Disorder
  • +10 more
  • Loncastuximab Tesirine
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United

Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
May 10, 2022

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Italy (Consolidation with ADCT-402 (loncastuximab

Recruiting
  • Relapsed Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
  • Brescia, Italy
  • +19 more
Apr 22, 2022

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Recurrent DLBCL, Recurrent Mantle Cell Lymphoma, Refractory DLBCL Trial in Duarte (Autologous

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 28, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021

Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma Trial in China (Zanubrutinib)

Completed
Has Results
  • Refractory Mantle Cell Lymphoma
  • Relapsed Mantle Cell Lymphoma
  • Beijing, Beijing, China
  • +13 more
Oct 8, 2021

Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma Trial

Terminated
Has Results
  • Ann Arbor Stage I Mantle Cell Lymphoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 16, 2021

B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic

Terminated
  • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
  • +16 more
  • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 28, 2021

Advanced Solid Tumor, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Tumor Trial in Chicago (other, biological, drug)

Unknown status
Has Results
  • Advanced Solid Neoplasm
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Chicago, Illinois
    Northwestern University
Oct 27, 2020